Fierce Pharma
AUGUST 1, 2023
As COVID-19 revenues ebb and flow—but mostly ebb—Pfizer is eyeing the cost-cutting shears. | Paxlovid generated just $143 million in worldwide sales for the second quarter, while mRNA vaccine Comirnaty brought home $1.4 billion. Against that backdrop, Pfizer reported total second quarter revenues of $12.7 billion, down a whopping 53% operationally from the same period last year.
MedCity News
AUGUST 1, 2023
Last week, the CFO of Universal Health Services stated that the company chooses which patients to treat based on whose insurance plans offer the highest payments. The comments have sparked some media attention, but healthcare finance experts say the practice of cherry-picking patients is nothing new to the industry.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
AUGUST 1, 2023
Bristol Myers Squibb and AstraZeneca have quickly resolved patent infringement lawsuits around their blockbuster cancer immunotherapies. | Bristol Myers Squibb and AstraZeneca have quickly resolved patent infringement lawsuits around their blockbuster PD-1/L1 and CTLA-4 cancer immunotherapies.
PharmaTech
AUGUST 1, 2023
AstraZeneca, via its subsidiary Alexion Pharmaceuticals, will purchase a portfolio of preclinical rare disease gene therapies from Pfizer in a deal worth up to $1 billion.
Fierce Pharma
AUGUST 1, 2023
Merck’s $10.8 billion acquisition of Prometheus Biosciences | Merck’s $10.8 billion acquisition of Prometheus Biosciences earlier this year gave the New Jersey company increased diversity in its portfolio, much needed considering its overwhelming dependence on cancer juggernaut Keytruda. But buying out the San Diego immunology specialist has not satisfied Merck’s appetite for M&A, executives said.
MedCity News
AUGUST 1, 2023
Even as value-based care finds its footing and expands further, team-based approaches to care delivery incorporating pharmacists as crucial connections are already bearing results—helping provider organizations achieve 5-star CMS ratings for medication adherence, driving down costs, and driving up the quality of life for patients.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
AUGUST 1, 2023
AI can index company narratives relative to strategy, opportunities, and threats, and create benchmarks to watch over time related to sentiment, intensity, and impressions. Ultimately these can be tied back to ROI and stakeholder value that move past typical marketing performance metrics or traditional brand metrics.
Fierce Pharma
AUGUST 1, 2023
After gaining its first FDA approval in its two-plus decades of existence, TheracosBio has made a CEO switch, replacing Al Collinson, Ph.D., with Brian Connelly. | After gaining its first FDA approval in its two-plus decades of existence, TheracosBio has made a CEO switch. The company is replacing Al Collinson, Ph.D., with Brian Connelly. Collinson, who ran Theracos for more than 14 years, guided the development of SGLT2 diabetes drug Brenzavvy, which was blessed by the FDA in January.
MedCity News
AUGUST 1, 2023
We need a streamlined approach where stakeholders can perform all critical tasks — from enrollment and patient consent to prior authorization, from real-time benefit checks to financial assistance — on a central platform powered by a business rules engine, automated workflows, and real-time analytics.
Fierce Pharma
AUGUST 1, 2023
Eight months after Briumvi’s initial green light in the U.S., TG Therapeutics is preparing to debut its multiple sclerosis antibody on the world stage. | European specialty pharmaceutical company Neuraxpharm will throw TG an upfront payment of $140 million—plus an additional $12.5 million upon Briumvi’s first EU launch—to chip in on commercialization of TG’s CD20-targeting drug outside the U.S.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
AUGUST 1, 2023
HerMD recently raised $18 million in a Series A-1 funding round. The company offers in-person and virtual women’s healthcare that focuses on menopause and sexual health. It is using its new capital to open more brick-and-mortar women’s health centers across the country.
Pharmaceutical Technology
AUGUST 1, 2023
BioNTech has acquired all the remaining shares of technology company InstaDeep in a deal valued at €500m ($549m) in cash.
MedCity News
AUGUST 1, 2023
TG Therapeutics’ multiple sclerosis drug Briumvi will be commercialized in Europe by Neuraxpharm. The Germany-based company paid $140 million up front for certain rights to the drug, which received European Commission approval in June.
Medgadget
AUGUST 1, 2023
Researchers at the University of Hong Kong have developed a microneedle patch for the drug-free treatment of skin infections, such as acne. Acne is often treated using antibiotics, but these have limited effectiveness over the long term and can result in drug-resistant bacteria. In an effort to develop a drug-free alternative, these researchers have created a microneedle patch that is ultrasound responsive.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
AUGUST 1, 2023
Hello Alpha launched Ahead with Alpha, a weight management program for employers. It offers access to primary care providers trained in obesity care, medication management through weight loss drugs like GLP-1s, nutrition counseling with a registered dietitian and progress tracking.
PharmaTimes
AUGUST 1, 2023
The approval involves the roll-out of a non-cancer chronic pain study for up to 5,000 patients - News - PharmaTimes
MedCity News
AUGUST 1, 2023
The average total monthly premium for Medicare Part D coverage is expected to be $55.50 in 2024, down from $56.49 in 2023, according to CMS.
PharmExec
AUGUST 1, 2023
New deal to focus on commercialization efforts in Latin America.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
MedCity News
AUGUST 1, 2023
Revolution Medicines is acquiring EQRx in an all-stock deal bringing that company’s more than $1 billion in cash. It marks the end for EQRx, a company that aimed to develop and commercialize lower-cost drugs for cancer and other diseases.
PharmaTimes
AUGUST 1, 2023
First-in-human study to be undertaken at the Manchester University Hospitals NHS Foundation Trust - News - PharmaTimes
Clarify Health
AUGUST 1, 2023
More than one in every five children falls behind in recommended vaccinations before their second birthday. In support of National Immunization Awareness Month, the Clarify Health Institute explores key aspects of pediatric vaccination trends and reinforces their clinical importance by addressing common misconceptions and presenting insights from empirical analyses of vaccination rates among patients aged 0-2 years.
PharmExec
AUGUST 1, 2023
Sharon Suchotliff, associate principal at ZS and lead for patient centricity, discusses why patient centricity has become a business imperative for life sciences companies. Sharon delves into the measurement of patient centricity, provides examples of how different companies have approached this and ZS’s approach for Patient Outcomes Impact (POI).
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Evolve Your Success
AUGUST 1, 2023
Whether as a clinical specialist or support manager, your determination and passion will lead you to greatness. Seize the chance to make a difference in patients’ lives, and let your journey inspire others to reach for the stars. In this episode, Lejla Sarajlic , Director of Marketing, Lung Cancer, takes us on her incredible journey from being a clinical specialist to reaching the pinnacle of her career in medical sales.
Spotio
AUGUST 1, 2023
How well do you know your sales pipeline? If your answer is anything short of, “Like the back of my hand,” your team probably doesn’t close many deals. After all, your pipeline knowledge directly affects your ability to plan field sales strategies, make real-time decisions, and grow revenue. Thankfully, pipeline reporting will give you all of the information you need to properly coach your reps, boost sales, and achieve more success for your company.
PharmExec
AUGUST 1, 2023
Industry veteran Charles Pirraglia demystifies the journey of bringing life-changing therapies to the Canadian market, from understanding drug pricing to navigating direct-to-consumer advertising rules.
Zymewire
AUGUST 1, 2023
Conquering a Giant As the world comes together to observe World Lung Cancer Day, Zymewire sheds light on the ongoing efforts of biotech and pharmaceutical companies in developing novel treatments for this devastating disease. Lung cancer remains one of the leading causes of cancer-related deaths worldwide, exceeding deaths from prostate, colon, and breast cancers combined.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
PharmExec
AUGUST 1, 2023
Patient centricity is an imperative focus for the advancement of life sciences businesses, and Sharon Suchotliff from ZS delves into this topic by sharing her keen insights.
PharmaVoice
AUGUST 1, 2023
Afaxys is a self-described "socially conscious" contraceptive healthcare company serving an unusual demographic for pharma: the public health sector.
PharmaTech
AUGUST 1, 2023
Interoperability difficulties resulting from discrepancies in preferred programming languages can be resolved via statistical computing environments.
PharmaVoice
AUGUST 1, 2023
Much like the year she first graced store shelves, Barbie has taken over the world. But now, the women's health landscape looks a whole lot different.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
238 
Let's personalize your content